Evidence map›Paper›PMID 34105268›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021

Adipocyte Fatty Acid Binding Protein Promotes the Onset and Progression of Liver Fibrosis via Mediating the Crosstalk between Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells.

Xiaoping Wu, Lingling Shu, Zixuan Zhang, Jingjing Li, Jiuyu Zong, Lai Yee Cheong, Dewei Ye, Karen S L Lam, Erfei Song, Cunchuan Wang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 94 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. World journal of gastroenterology · 2025
    Article
  19. The role of JNK signaling pathway in organ fibrosis.Journal of advanced research · 2025
    Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Xiaoping WuState Key Laboratory of Pharmaceutical Biotechnology, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Lingling ShuState Key Laboratory of Pharmaceutical Biotechnology, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Zixuan ZhangState Key Laboratory of Pharmaceutical Biotechnology, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Jingjing LiDepartment of Pharmacology and Pharmacy, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Jiuyu ZongState Key Laboratory of Pharmaceutical Biotechnology, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Lai Yee CheongState Key Laboratory of Pharmaceutical Biotechnology, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Dewei YeJoint Laboratory of Guangdong and Hong Kong on Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou, 510000, China.
Karen S L LamState Key Laboratory of Pharmaceutical Biotechnology, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Erfei SongDepartment of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, 510630, China.
Cunchuan WangDepartment of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, 510630, China.
Aimin XuState Key Laboratory of Pharmaceutical Biotechnology, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Ruby L C HooState Key Laboratory of Pharmaceutical Biotechnology, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.ORCID 0000-0001-9633-7078
Chinese University of Hong Kong · HKPharmaceutical Biotechnology (Czechia) · CZFirst Affiliated Hospital of Jinan University · CNGuangdong Pharmaceutical University · CNInstitut de Recherche et d’Innovation · FRSun Yat-sen University · CNUniversity of Hong Kong · HK

Funding

Area of Excellence Scheme from Research Grants Council of the Hong Kong Special Administrative Region AOE/M-707/18Collaborative research fund from Research Grants Council of the Hong Kong Special Administrative Region C7037-17WHealth and Medical Research Fund 02131906Shenzhen Basic Research Grant 201605303000678
6 · The paper itself

Abstract

Development of liver fibrosis results in drastic changes in the liver microenvironment, which in turn accelerates disease progression. Although the pathological function of various hepatic cells in fibrogenesis is identified, the crosstalk between them remains obscure. The present study demonstrates that hepatic expression of adipocyte fatty acid binding protein (A-FABP) is induced especially in the liver sinusoidal endothelial cells (LSECs) in mice after bile duct ligation (BDL). Genetic ablation and pharmacological inhibition of A-FABP attenuate BDL- or carbon tetrachloride-induced liver fibrosis in mice associating with reduced collagen accumulation, LSEC capillarization, and hepatic stellate cell (HSC) activation. Mechanistically, elevated A-FABP promotes LSEC capillarization by activating Hedgehog signaling, thus impairs the gatekeeper function of LSEC on HSC activation. LSEC-derived A-FABP also acts on HSCs in paracrine manner to potentiate the transactivation of transforming growth factor β1 (TGFβ1) by activating c-Jun N-terminal kinase (JNK)/c-Jun signaling. Elevated TGFβ1 subsequently exaggerates liver fibrosis. These findings uncover a novel pathological mechanism of liver fibrosis in which LSEC-derived A-FABP is a key regulator modulating the onset and progression of the disease. Targeting A-FABP may represent a potential approach against liver fibrosis.

Indexed as

AnimalsCapillariesCarbon TetrachlorideDisease Models, AnimalEndothelial CellsFatty Acid-Binding ProteinsGene Expression RegulationHedgehog ProteinsHepatic Stellate CellsHumansJNK Mitogen-Activated Protein KinasesLiverLiver CirrhosisMiceProtein BindingSignal TransductionCarbon TetrachlorideFabp4 protein, mouseFatty Acid-Binding ProteinsHedgehog ProteinsJNK Mitogen-Activated Protein KinasesTgfb1 protein, mouseTransforming Growth Factor beta1A-FABPhepatic stellate cellsliver fibrosisliver sinusoidal endothelial cellsTGFβ1

Identifiers

PMID34105268
PMCPMC8188197
OpenAlexW3149556147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.